Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or a penny per share as opposed to a net income of $3.2 million or 8 cents per share in the comparable period of 2008. The Zacks Consensus Estimate for the reported quarter was for a gain of 7 cents.

The loss in the quarter was attributable to higher operating expenses. We remain concerned about the company’s dependence on partners for generating revenues, as the strategy has inherent risks. Furthermore, the competitive life sciences industry is characterized by rapid and continuous technological innovation which further challenges Luminex.

The company’s strategy to grow by acquisitions is also risky. In view of these concerns, we downgrade the stock to Underperform.

Zacks Investment Research

1. (LMNX) Luminex Corporation Posts LossLuminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or 1 cent per share...
2. (POT) Potash Corporation – Bear of the DayWe downgrade Potash Corporation (POT), the world’s leading producer of potash and fertilizer, to Underperform....
3. (RAD) Rite Aid Corporation – Bear of the DayManagement at Rite Aid Corporation (RAD) was executing a turnaround strategy centered on increasing the...
4. (RAD) Rite Aid Corporation – Bear of the DayManagement at Rite Aid Corporation (RAD) was executing a turnaround strategy centered on increasing the...
5. Top Short Equity Funds – Mutual Fund CommentaryToday we are featuring top-performing “Short” equity mutual funds, which can buy or sell securities...
6. (LMNX) Luminex Corp – next-year estimate pegged at a whopping 359% earnings growth projectionLuminex Corp. (LMNX) is fresh off the heels of a great quarter in which the...

Search Posts by Tag: LMNX | Luminex Corporation | Healthcare

RSS Feeds by Tag: LMNX | Luminex Corporation | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author